# Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

> **NCT01284530** · PHASE1,PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** TPM XR

## Key facts

- **NCT ID:** NCT01284530
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284530, "Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01284530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*